Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PI3Kdelta/gamma inhibitor ZX-101A

An orally bioavailable inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration of PI3Kdelta/gamma inhibitor ZX-101A, this agent targets and inhibits the PI3K delta and gamma isoforms and prevents the activation of the PI3K/AKT-mediated signaling pathway. This may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. ZX-101A may also promote anti-tumor immunity. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies. By selectively targeting these isoforms, PI3K signaling in normal, non-neoplastic cells is minimally impacted or not affected at all, which minimizes the side effect profile for this agent.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:PI3K-d/g inhibitor ZX-101A
Code name:ZX 101A
ZX-101A
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search